Current and historical daily PE Ratio for Phio Pharmaceuticals Corp (
FRA:44R3
) from 2014 to Jun 04 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Phio Pharmaceuticals stock (FRA:44R3) PE ratio as of Jun 04 2024 is 0.
More Details
Phio Pharmaceuticals Corp (FRA:44R3) PE Ratio (TTM) Chart
Phio Pharmaceuticals Corp (FRA:44R3) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1208
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Phio Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-04 | At Loss | 2023-12-12 | At Loss |
| 2024-02-14 | At Loss | 2023-12-11 | At Loss |
| 2024-02-13 | At Loss | 2023-12-08 | At Loss |
| 2024-02-12 | At Loss | 2023-12-07 | At Loss |
| 2024-02-09 | At Loss | 2023-12-06 | At Loss |
| 2024-02-08 | At Loss | 2023-12-05 | At Loss |
| 2024-02-07 | At Loss | 2023-12-04 | At Loss |
| 2024-02-06 | At Loss | 2023-12-01 | At Loss |
| 2024-02-05 | At Loss | 2023-11-30 | At Loss |
| 2024-02-02 | At Loss | 2023-11-29 | At Loss |
| 2024-02-01 | At Loss | 2023-11-28 | At Loss |
| 2024-01-31 | At Loss | 2023-11-27 | At Loss |
| 2024-01-30 | At Loss | 2023-11-24 | At Loss |
| 2024-01-29 | At Loss | 2023-11-23 | At Loss |
| 2024-01-26 | At Loss | 2023-11-22 | At Loss |
| 2024-01-25 | At Loss | 2023-11-21 | At Loss |
| 2024-01-24 | At Loss | 2023-11-20 | At Loss |
| 2024-01-23 | At Loss | 2023-11-17 | At Loss |
| 2024-01-22 | At Loss | 2023-11-16 | At Loss |
| 2024-01-19 | At Loss | 2023-11-15 | At Loss |
| 2024-01-18 | At Loss | 2023-11-14 | At Loss |
| 2024-01-17 | At Loss | 2023-11-13 | At Loss |
| 2024-01-16 | At Loss | 2023-11-10 | At Loss |
| 2024-01-12 | At Loss | 2023-11-09 | At Loss |
| 2024-01-11 | At Loss | 2023-11-08 | At Loss |
| 2024-01-10 | At Loss | 2023-11-07 | At Loss |
| 2024-01-09 | At Loss | 2023-11-06 | At Loss |
| 2024-01-08 | At Loss | 2023-11-03 | At Loss |
| 2024-01-05 | At Loss | 2023-11-02 | At Loss |
| 2024-01-04 | At Loss | 2023-11-01 | At Loss |
| 2024-01-03 | At Loss | 2023-10-31 | At Loss |
| 2024-01-02 | At Loss | 2023-10-30 | At Loss |
| 2024-01-01 | At Loss | 2023-10-27 | At Loss |
| 2023-12-29 | At Loss | 2023-10-26 | At Loss |
| 2023-12-28 | At Loss | 2023-10-25 | At Loss |
| 2023-12-27 | At Loss | 2023-10-24 | At Loss |
| 2023-12-25 | At Loss | 2023-10-23 | At Loss |
| 2023-12-22 | At Loss | 2023-10-20 | At Loss |
| 2023-12-21 | At Loss | 2023-10-19 | At Loss |
| 2023-12-20 | At Loss | 2023-10-18 | At Loss |
| 2023-12-19 | At Loss | 2023-10-17 | At Loss |
| 2023-12-18 | At Loss | 2023-10-16 | At Loss |
| 2023-12-15 | At Loss | 2023-10-13 | At Loss |
| 2023-12-14 | At Loss | 2023-10-12 | At Loss |
| 2023-12-13 | At Loss | 2023-10-11 | At Loss |
Phio Pharmaceuticals Corp (FRA:44R3) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Phio Pharmaceuticals Corp
NAICS : 325412
SIC : 2834
ISIN : US74979C8082
Description
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers